Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07169825 · ClinicalTrials.gov registry record · NA
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
A NA study, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT07169825: Recruiting NA study, sponsored by M.D. Anderson Cancer Center.
NCT07169825 is a NA study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07169825, a NA study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
Interventions
- DRUG Lu-177
- OTHER SPECT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-03-30 |
| Est. Completion | 2028-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07169825
The ClinicalTrials.gov registry entry for NCT07169825 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lu-177 is the first listed.
NCT07169825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07169825 about?
NCT07169825 is a clinical study titled "Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function". To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
What is the current status of trial NCT07169825?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2026-03-30. Estimated completion is 2028-09-01.
What interventions are being tested in trial NCT07169825?
The interventions under investigation include: Lu-177 (DRUG), SPECT (OTHER).
Who is sponsoring clinical trial NCT07169825?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.